BioNTech SE (BNTX) AI Stock Analysis

Compare

4,604 Followers

Top Page

BioNTech SE

(NASDAQ:BNTX)

Rating:58Neutral

Price Target:

$109.00

▲(1.39%Upside)

BioNTech's overall stock score of 58 reflects the company's robust financial position and strategic advancements in oncology and vaccine development as key strengths. However, significant financial challenges, including ongoing losses, high R&D expenses, and settlement costs, weigh heavily on the score. The technical analysis and valuation further underscore the need for cautious optimism, given the current neutral trend and negative P/E ratio.

Positive Factors

Manufacturing Capability

The acquisition expands BioNTech's manufacturing capability due to CureVac's state-of-the-art research and manufacturing site in Tübingen.

Regulatory Approval

BioNTech SE has been granted Orphan Drug Designation for a recombinant bispecific antibody for the treatment of small cell lung cancer, providing for seven years of market exclusivity post-approval.

Strategic Acquisition

The acquisition of CureVac by BioNTech is viewed as a strategic move to eliminate legal and financial uncertainties related to ongoing litigation over mRNA intellectual property.

Negative Factors

Clinical Data Risks

Risks include negative data for BNT122, BNT111, BNT113, BNT116, BNT211, BNT316, BNT323, and BNT327.

Market Uptake

Risks include slower-than-expected market uptake and failure to advance other programs in a timely manner.

BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$25.84B

Dividend YieldN/A

Average Volume (3M)1.03M

Price to Earnings (P/E)―

Beta (1Y)0.86

Revenue Growth0.58%

EPS Growth-764.64%

CountryUS

Employees6,772

SectorHealthcare

Sector Strength44

IndustryBiotechnology

Share Statistics

EPS (TTM)-2.04

Shares Outstanding246,236,000

10 Day Avg. Volume588,593

30 Day Avg. Volume1,029,309

Financial Highlights & Ratios

PEG Ratio-0.27

Price to Book (P/B)1.70

Price to Sales (P/S)0.00

P/FCF Ratio2.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$140.10

Price Target Upside30.31% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

BioNTech SE Business Overview & Revenue Model

Company DescriptionBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes MoneyBioNTech makes money primarily through the development and commercialization of its mRNA-based therapies and vaccines. A significant portion of its revenue comes from its COVID-19 vaccine, Comirnaty, which was developed in partnership with Pfizer. This partnership involves a profit-sharing agreement where BioNTech receives a share of the revenue generated from the vaccine sales. Additionally, BioNTech earns revenue through collaborations and licensing agreements with other pharmaceutical companies, governments, and health organizations, which may include milestone payments, royalties, and research funding. The company also invests in the development of other therapeutic areas, such as oncology, which could become future revenue streams as these products reach commercialization.

BioNTech SE Earnings Call Summary

Earnings Call Date:May 05, 2025

(Q1-2025)

% Change Since: 2.45%|

Next Earnings Date:Aug 04, 2025

Earnings Call Sentiment Neutral

The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.

Q1-2025 Updates

Positive Updates

Advancements in Oncology Programs

BioNTech presented new clinical data for their bispecific immunomodulator BNT327 and mRNA cancer immunotherapies, showing potential to establish new standards of care in oncology. They are advancing towards commercialization with the first BLA submission for BNT323 planned by the end of 2025.

COVID-19 Vaccine Developments

BioNTech is preparing for a variant-adapted COVID-19 vaccine rollout and maintains a strong financial position to support these developments.

Strong Financial Position

Despite a net loss, BioNTech ended the quarter with €15.9 billion in total cash plus security investments, indicating robust financial health.

Negative Updates

Decreased Revenue and Increased Net Loss

BioNTech reported total revenues of approximately €183 million for Q1 2025, a slight decrease from €188 million in Q1 2024. The net loss for the first quarter of 2025 was €416 million, compared to a net loss of €315 million in the prior-year period.

High R&D and Settlement Costs

R&D expenses increased to €526 million, driven by late-stage clinical studies. Additionally, BioNTech faced significant settlement costs with NIH and the University of Pennsylvania, totaling approximately US$1.2 billion.

Company Guidance

In BioNTech's first quarter 2025 earnings call, the company provided guidance on several key metrics. They reported total revenues of approximately €183 million for the quarter, primarily from COVID-19 vaccine sales, compared to €188 million in the first quarter of 2024, reflecting expected seasonality. BioNTech's research and development expenses reached €526 million, up from €508 million in the prior-year period, driven by the advancement of late-stage clinical studies, including those for BNT327. Selling, general, and administrative expenses were €121 million, down from €133 million due to reduced external services. The company recorded a net loss of €416 million, compared to a €315 million loss in the same period last year, with a basic and diluted loss per share of €1.73 versus €1.31 previously. BioNTech ended the quarter with a strong cash position of €15.9 billion, despite significant outflows related to acquisitions and settlements. For the full year, BioNTech reaffirmed its 2025 financial guidance, projecting revenues between €1.7 billion and €2.2 billion, R&D expenses from €2.6 billion to €2.8 billion, SG&A expenses between €650 million and €750 million, and capital expenditures ranging from €250 million to €350 million.

BioNTech SE Financial Statement Overview

Summary

BioNTech showcases a robust balance sheet with a strong equity base and low debt, yet faces challenges with profitability and cash flow volatility. Addressing these operational issues is crucial for long-term growth.

Income Statement

Neutral

BioNTech's income statement reflects significant challenges in profitability. Recent TTM figures show negative net and EBIT margins, indicating operational inefficiencies. Although the company had strong revenue in previous years, recent declines highlight potential revenue instability.

Balance Sheet

Positive

BioNTech's balance sheet is robust, with a strong equity base and low levels of debt, resulting in a favorable debt-to-equity ratio. The equity ratio remains solid, underscoring financial stability. However, recent trends in reduced stockholders' equity warrant caution.

Cash Flow

Neutral

The cash flow analysis reveals a volatile free cash flow trend, with recent TTM figures showing a significant decline. While operating cash flow remains positive, the substantial drop in free cash flow raises concerns about cash management efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.75B	2.75B	3.82B	17.31B	18.98B	482.30M
Gross Profit	2.17B	2.21B	3.22B	14.32B	16.07B	423.00M
EBITDA	-445.59M	-367.10M	1.38B	12.86B	15.00B	-105.10M
Net Income	-768.64M	-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet
Total Assets	21.18B	22.53B	23.01B	23.28B	15.83B	2.32B
Cash, Cash Equivalents and Short-Term Investments	14.11B	16.78B	16.55B	14.06B	2.07B	1.35B
Total Debt	293.00M	254.20M	219.10M	212.20M	301.50M	240.19M
Total Liabilities	2.26B	3.12B	2.76B	3.22B	3.94B	946.77M
Stockholders Equity	18.93B	19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow
Free Cash Flow	-1.17B	-244.60M	4.67B	13.21B	735.70M	-98.90M
Operating Cash Flow	-234.59M	207.70M	5.37B	13.58B	889.70M	-13.50M
Investing Cash Flow	1.47B	-2.08B	-6.95B	-35.30M	-566.10M	-144.80M
Financing Cash Flow	-51.90M	-45.90M	-778.60M	-1.42B	94.20M	894.70M

BioNTech SE Technical Analysis

Technical Analysis Sentiment

Positive

Last Price107.51

Price Trends

50DMA

103.14

Positive

100DMA

103.46

Positive

200DMA

109.56

Negative

Market Momentum

MACD

1.18

Positive

RSI

56.99

Neutral

STOCH

74.86

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 107.51 is above the 20-day moving average (MA) of 106.64, above the 50-day MA of 103.14, and below the 200-day MA of 109.56, indicating a neutral trend. The MACD of 1.18 indicates Positive momentum. The RSI at 56.99 is Neutral, neither overbought nor oversold. The STOCH value of 74.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.

BioNTech SE Risk Analysis

BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

BioNTech SE Peers Comparison

Overall Rating

UnderperformOutperform

Sector (49)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	78 Outperform	$12.79B	11.47	22.69%	―	25.11%	46.46%
ARGX	68 Neutral	$34.48B	39.68	17.33%	―	78.01%	―
ALNY	66 Neutral	$42.09B	―	-414.62%	―	17.21%	21.16%
SWTX	61 Neutral	$3.54B	―	-51.57%	―	730.42%	31.63%
BNTX	58 Neutral	$25.84B	―	-3.87%	―	0.58%	-764.64%
Sector *	49 Neutral	AU$2.48B	4.18	-64.25%	2.84%	36.51%	13.13%
MRNA	48 Neutral	$10.50B	―	-29.34%	―	-38.25%	44.29%

* Healthcare Sector Average

Performance Comparison

BNTX

BioNTech SE

108.26

28.40

35.56%

ALNY

Alnylam Pharma

329.77

81.09

32.61%

ARGX

Argenx Se

545.11

109.82

25.23%

GMAB

Genmab

20.44

-4.71

-18.73%

MRNA

Moderna

30.28

-85.67

-73.89%

SWTX

Springworks Therapeutics

46.99

9.71

26.05%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025